NewAmsterdam Pharma N.V. Quarterly Balance Sheet
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NewAmsterdam Pharma N.V. financial position
As of Jun 30, 2026, NewAmsterdam Pharma N.V. reported total assets of $704.5 million, down 13.6% from a year earlier against total liabilities of $73.0 million. Shareholders' equity stood at $631.4 million, or 89.6% of assets. The company held $424.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 9.03, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
NewAmsterdam Pharma N.V. balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 424.15M | 457.61M | 490.00M | 538.41M | 563.86M | 748.42M | 771.74M | 422.73M | 430.71M | 481.15M | 340.45M | — |
| Short-Term Investments | 209.70M | 178.50M | 146.24M | 164.54M | 175.30M | 60.06M | 62.45M | — | — | — | — | — |
| Total Current Assets | 659.21M | 658.04M | 675.70M | 732.33M | 769.85M | 817.30M | 863.41M | 437.87M | 445.35M | 487.82M | 346.79M | — |
| Property, Plant & Equipment | 411.00K | 379.00K | 383.00K | 323.00K | 312.00K | 238.00K | 242.00K | 231.00K | 234.00K | 101.00K | 46.00K | — |
| Long-Term Investments | 44.41M | 71.24M | 92.61M | 53.09M | 44.17M | — | — | — | — | — | — | — |
| Total Assets | 704.45M | 732.64M | 769.28M | 786.43M | 815.11M | 818.41M | 864.62M | 439.19M | 446.69M | 488.46M | 347.10M | — |
| Accounts Payable | 5.42M | 8.09M | 8.97M | 3.63M | 5.89M | 6.09M | 4.74M | 7.04M | 5.28M | 8.54M | 16.92M | — |
| Total Current Liabilities | 72.97M | 67.42M | 85.79M | 58.27M | 36.51M | 40.91M | 106.92M | 41.26M | 45.31M | 59.73M | 49.90M | — |
| Total Liabilities | 73.03M | 67.42M | 85.85M | 58.36M | 36.62M | 41.05M | 107.12M | 60.33M | 59.25M | 76.66M | 58.70M | — |
| Shareholders' Equity | 631.42M | 665.22M | 683.43M | 728.07M | 778.50M | 777.36M | 757.50M | 378.86M | 387.44M | 411.80M | 288.39M | 331.83M |
| Retained Earnings | -874.97M | -810.83M | -762.39M | -687.47M | -615.46M | -598.10M | -558.57M | -466.39M | -449.75M | -410.74M | -316.97M | — |
| Net Cash (Debt) | 633.85M | 636.11M | 636.24M | 702.95M | 739.16M | 808.48M | 834.19M | 422.73M | 430.71M | 481.15M | 340.45M | — |
| Shares Outstanding | 117.65M | 116.64M | 114.40M | 113.17M | 112.51M | 112.17M | 108.06M | 92.17M | 90.02M | 89.72M | 82.47M | — |
This table shows 12 quarterly periods of NewAmsterdam Pharma N.V.'s balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow NAMS's reporting calendar. What is a balance sheet?